远程与现场研究评估(RISE)试验1/3:去中心化试验方法对招募效率、保留、生物样本采集和治疗利用影响的随机对照试验方案
RISE Above Smoking 是一项多中心随机对照试验,计划随机200名成年吸烟者比较远程与现场入组访视,入组合格者再次随机比较远程与现场治疗和评估访视。所有参与者接受8周联合尼古丁替代疗法和自助手册,随访3个月,主要结局包括招募效率、保留、治疗利用/依从性和生物样本完成率,并评估戒烟这一关键次要临床结局。
要点
- 远程试验的获益与局限缺乏严格证据,RISE旨在提供随机对照证据。
- RISE Above Smoking聚焦戒烟场景,比较远程与现场入组、治疗和评估访视。
- 主要结局涵盖招募效率、保留、治疗利用/依从性和生物样本完成率。
核心结论
- RISE试验将提供关于远程试验方法对试验效率和严谨性影响的新颖、严谨证据,并评估这些效应在不同临床背景和参与者特征中的普遍性。
研究设计与样本
- RISE由针对3个不同使用场景的独立随机对照试验组成,本方案聚焦RCT 1(RISE Above Smoking)。
- RCT 1将成年吸烟者随机分配至远程或现场入组访视(书面知情同意和资格筛查)。
- 入组合格参与者将再次随机分配至远程或现场治疗和评估访视。
- 招募将持续至200名成年吸烟者开始治疗。
- 所有参与者接受8周联合尼古丁替代疗法(根据吸烟率选择14或21 mg透皮尼古丁贴片,联合2 mg尼古丁含片)和印刷版自助指南,并随访至3个月。
关键数值与推荐
- 主要结局包括招募效率、保留、治疗利用/依从性和生物样本完成率。
- 关键次要临床结局为戒烟。
- RCT 1已在ClinicalTrials.gov预注册(NCT06822049,2025年2月12日)。
临床怎么用
- 该试验结果可为研究团队设计远程或去中心化临床试验时提供关于招募、保留、治疗依从性和生物样本采集方面的证据参考。
局限性
- 原文指出远程试验的获益证据薄弱,主要基于轶事报告、非对照研究和专家意见;对技术障碍和试验严谨性方面的局限同样缺乏证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Remote trials (i.e., virtual or decentralized trials), in which patients receive some or all treatment and provide study data without the need to travel to a clinic or medical center, have emerged as a promising approach to conducting clinical trials. However, evidence for the hypothesized benefits of remote trials is weak, consisting primarily of anecdotal reports, uncontrolled studies, and expert opinion. The same is true for hypothesized limitations of remote trials such as technological barriers and aspects of trial rigor. A stronger evidence base is needed to evaluate the impact of remote trials. METHODS: Remote vs. In-Person Study Evaluation (RISE) was developed to examine the benefits and limitations of remote clinical trials and consists of separate randomized controlled trials (RCTs) for 3 different use cases. In RISE RCT 1 (RISE Above Smoking), the focus of this protocol paper, adults who smoke (AWS) cigarettes will be randomized to Remote vs. In-Person Intake Visit (written consent and eligibility screening). Intake-eligible participants will be re-randomized to Remote vs. In-Person Treatment and Assessment Visits. Recruitment will continue until 200 AWS initiate treatment. All participants will receive 8 weeks of combination nicotine replacement therapy (NRT; 14 or 21 mg transdermal nicotine patch, based on smoking rate, and 2 mg nicotine lozenges) and a printed self-help guide, and will be assessed through 3-month follow-up. Primary outcomes include accrual efficiency, retention, treatment utilization/adherence, and biospecimen completion rates. A key secondary clinical outcome (smoking cessation) will also be assessed. Subsequently, RISE RCTs 2 and 3 will employ harmonized timelines and outcomes in smaller (N = 100 participants who initiate treatment in each) single-site evaluations of remote vs. in-person trial components in different contexts: an mHealth intervention for people with depression symptoms and an opioid overdose education and naloxone intervention for people with opioid/stimulant use disorder. DISCUSSION: The RISE RCTs will provide novel, rigorous evidence regarding the impact of remote trial methods on trial efficiency and rigor, including the degree to which these effects generalize across clinical contexts and participant characteristics. TRIAL REGISTRATION: RCT 1 was preregistered on February 12 2025, on ClinicalTrials.gov, NCT06822049. https://clinicaltrials.gov/study/NCT06822049 . (RCTs 2 and 3 will be registered prior to initiating recruitment to those trials.).
引用
- Hawk LW, Schnoll RA, Dahne J, et al. Remote vs. In-Person Study Evaluation (RISE) Trial 1 of 3 to examine the impact of decentralized trial methods on accrual efficiency, retention, biospecimen capture, and treatment utilization: study protocol for a multi-center randomized controlled trial in the context of smoking cessation (RISE Above Smoking). Trials. 2026. PMID: 42947186. doi:10.1186/s13063-026-09910-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。